Hospital

Sachin Nagrani, MD, the medical director of Heal, discusses his predictions for the future as we continue to fight the COVID-19 pandemic.

Although prevention decreased with time, a third booster dose was still highly effective at preventing severe illness with COVID-19.

Data from the CALIBRATE and CAPELLA trials show high rates of virologic suppression with the capsid inhibitor.

The drug combination reduced the risk of disease progression by 34% versus the standard of care in first-line metastatic castration-resistant prostate cancer, clinical trial results show.

The variants include Alpha, Beta, Gamma, Delta, and Omicron, and the laboratory results are consistent with other analyses.

The best start for improving medication adherence in the pharmacy is initiating the conversations with patients that are necessary for their health.

Cohort H of the phase 1b/2 EV-103 trial enrolled patients with MIBC who were eligible for surgical treatment but ineligible for cisplatin-based chemotherapy.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses some of the common practices for the treatment of hypoactive sexual desire disorder in women and men.

Sachin Nagrani, MD, the medical director of Heal, discusses what pharmacists should know about the Omicron variant and other variants popping up globally.

Dalpiciclib added to fulvestrant (Faslodex) was found to significantly prolong progression-free survival compared with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

The safety of an anti-coronavirus hyperimmune intravenous immunoglobulin may be influenced by whether an individual is able to naturally generate SARS-CoV-2-neutralizing antibodies.

Just 2 of 41 nutritionists interviewed reported using a validated screener, while 4 others said they use other tools, such as screening questions developed by other organizations, results show.

The continued upward trend in testing and vaccination demand, coupled with staffing shortages, technology gaps, and never-ending to-do lists, exacerbates spikes in patient volume and workload for pharmacy professionals.

FDA to evaluate adagrasib for the treatment of patients with non–small cell lung cancer with tumors that have a KRAS G12C mutation.

Through the 240 weeks, numerically small median changes in eGFR and stable TC:HDL ratios were observed in both studies.

Results of CheckMate-9ER trial in first-line advanced renal cell carcinoma will be featured in 2 poster presentations at the American Society of Clinical Oncology 2022 Genitourinary Cancers Symposium.

Process helps prevent errors for individuals with chronic disorders who often have a higher risk of drug-drug interactions.

Using a transgenic mouse model of Alzheimer’s disease, scientists demonstrate a definitive connection with oxidative brain damage.

The common-weight loss plan synergizes with chemotherapy to triple survival time compared with the treatment alone in rigorous mouse models of PDAC, the analysis shows.

Ten quiz questions to assess your knowledge on common symptoms and treatments for hepatitis.

The drug pipeline is insufficient to meet the threat of antimicrobial resistance, and policy reforms are critically needed, according to the Biotechnology Innovation Organization.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses whether hypoactive sexual desire disorder is associated with psychological and/or emotional components.

All the participants were in the Beating Lung Cancer in Ohio study, which started before the COVID-19 pandemic.

Niraparib is associated with increased progression-free survival, regardless of the presence or absence of BRCA gene mutations.

Though target medication safety best practices was created with hospitals in mind, community pharmacies can also benefit from these practices.

NVX-CoV2373 (Novavax) was found to provide 100% protection against moderate and severe disease and 90.4% efficacy overall in a phase 3 trial last year.

Sachin Nagrani, MD, the medical director of Heal, discusses Pfizer’s research assessing an Omicron-specific vaccine for adults aged 18 to 55 years.

Adversity has disproportionately hurt certain populations, including essential workers and women, the results of a new analysis show.